The results showed that in patients with the HLA-A2+ phenotype with non-small cell lung cancer, overall survival was longer with Tedopi. (Photo credits: Adobe Stock – )
(CercleFinance.com) – OSE Immunotherapeutics will present, at the 2022 ESMO (European Society for Medical Oncology) conference, new analyzes on the phase 3 Atalante-1 trial of Tedopi immunotherapy in patients with advanced non-small cell lung cancer in secondary resistance after failure of checkpoint inhibitor therapy.
‘Tedopi shows overall clinical benefit over chemotherapy treatments. We are going to do everything we can to make this treatment available as quickly as possible for these patients,” says Alexis Vandier, CEO of OSE Immunotherapeutics.
The results showed that in patients with the HLA-A2+ phenotype with non-small cell lung cancer, overall survival was longer with Tedopi.